AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 111 min read$MCK

TYLER BRIAN S. sold $3.8M of MCK

TYLER BRIAN S. (Chief Executive Officer) sold 4,929 shares of MCKESSON CORP (MCK) at $763.00 ($3.76M total) on 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TYLER BRIAN S.
Published Jun 11, 2026, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but without any accompanying fundamental update, the signal is typically low-to-moderate and short-lived.

02

Market read

A scheduled CEO sale of ~$3.76M worth of McKesson shares was disclosed; absent other news, it is mainly a sentiment/positioning datapoint.

03

What to watch

The article provides only the sale size and post-transaction holdings; it does not disclose options, other concurrent insider trades, or any change in business outlook.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-11 (sale dated 2026-06-09)

Background

The article is an SEC Form 4 insider transaction disclosure (CEO/direct holdings) sourced from EDGAR.

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson CEO Tyler Brian S. filed an open-market sale of 4,929 shares on 2026-06-09 for ~$3.76M under a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any effect is more sentiment/positioning than a new fundamental catalyst.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale with no accompanying company-specific news (earnings, guidance, deal, or regulatory action) in the article.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

Regional

None indicated; US-listed large-cap healthcare distribution name.

Global

None indicated; no cross-border transaction or global regulatory event mentioned.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view.

Key entities

  • issuer
    McKesson Corporation

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Tyler Brian S.

    CEO/director who sold shares in an open-market transaction under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

news.alphastreet.com2 min
AUG 5
$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.

finance.biggo.com4 min
AUG 5
$MCKMedAI 8/10

McKesson’s (NYSE:MCK) Q2 CY2026 Sales Top Estimates

McKesson (NYSE:MCK) reported Q2 CY2026 sales of $105.4B, up 7.7% year on year, exceeding Wall Street revenue estimates by 1.2%. Non-GAAP adjusted EPS was $9.93, up from $8.26, beating consensus by 4.1%. Analysts expect revenue growth of 7.3% and full-year EPS to rise from $40.82 to $45.87.

financialcontent.com6 min